Coffee is one of the world's most widely consumed beverages, and previous research has linked its consumption to a lower risk of conditions such as type 2 diabetes and cardiovascular disease. However, the biological mechanisms behind these benefits remain unclear. A new Finnish study links habitual coffee consumption to healthier body composition and metabolic markers, while revealing distinct associations with sex hormones in men and women.

A randomized controlled trial (RCT) on the digital health application levidex has now been published in the international journal Multiple Sclerosis Journal – Experimental, Translational and Clinical.[1] The LAMONT study shows that levidex significantly and clinically improves disease-specific quality of life in people with multiple sclerosis (MS). The study specifically focused on people with MS who had a reduced quality of life. Researchers from GAIA investigated the efficacy of levidex in collaboration with the University of Duisburg-Essen, the Neuromed Campus Hohenlind, NeuroTransData, the Vincera Clinics in Bad Waldsee, and the University Medical Center Hamburg-Eppendorf. The results are particularly significant given that disease-modifying drugs do not adequately address the psychosocial and emotional burdens of the disease—the so-called “invisible symptoms”.

Men are more likely than women to catch tuberculosis (TB), finds a new study led by UCL (University College London) researchers.

New research which shows that taking the stairs could help you live longer.

A major new study reveals that climbing the stairs significantly reduces the risk of dying from cardiovascular disease.

Over the course of the study, people who regularly climb stairs were 39 per cent less likely to die from heart-related problems and 24 per cent less likely to die from any cause - compared with people who don't climb stairs as often.

The study also reveals that people who climbed the stairs were less likely to suffer major cardiovascular conditions such as a heart attack, stroke and heart failure.

Researchers and physicians at the Hopp Children's Cancer Center Heidelberg (KiTZ) and other leading cancer centers report an exceptional treatment success in an adolescent with an advanced, therapy-resistant kidney tumor. Using a novel, personalized T-cell therapy, they succeeded in completely pushing back the tumor disease despite multiple metastases. The individual compassionate-use treatment has now been published in the New England Journal of Medicine and underscores the potential of cellular Immunotherapies also for children and adolescents with solid tumors. The clinical trial building on these findings, planned for 2027, will be funded by the Dietmar Hopp Foundation with around 1.8 million euros over a period of four years at KiTZ.